The treatment of patients with metastatic colorectal cancer has changed profoundly over the past 25 years. In 1995, fluorouracil was the only active chemotherapy available for the disease, and long-term survival (ie, for at least 5 years) was rarely achieved with chemotherapy alone.1 Only patients with surgically resectable liver and lung metastases had a reasonable chance of long-term survival.1 Since then, more chemotherapeutic drugs have been approved, and median survival has increased to 2–3 years (from around 6–12 months), with 20–25% of patients surviving for at least 5 years.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου